{name}
{subtitle}
A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
city
~12 mi. (Herblay, France, +84 more cities)
facility
Site FR33012
drug
gemcitabine, +2 more drugs
drug type
chemotherapy, +1 more type
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
city
~13 mi. (Paris Campagne, France, +55 more cities)
facility
Hôpital Universitaire Pitié Salpêtrière (Adults only)
drug type
cellular therapy, +1 more type
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
city
~13 mi. (Paris Campagne, France, +26 more cities)
facility
Institut Curie /ID# 225829
condition
Malignant Solid Tumor, +1 more condition
drug
ABBV-637, +2 more drugs
drug type
chemotherapy, +1 more type
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
city
~13 mi. (Paris Campagne, France, +24 more cities)
facility
Institut Curie /ID# 223475
biomarker
ER Negative, +2 more biomarkers
condition
Breast Adenocarcinoma, +2 more conditions
drug
ABBV-368, +5 more drugs
drug type
chemotherapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~15 mi. (Clichy, France, +199 more cities)
facility
Hopital Beaujon ( Site 0439)
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~15 mi. (Bobigny, France, +158 more cities)
facility
Hopital Avicenne ( Site 0803)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~15 mi. (Bobigny, France, +122 more cities)
facility
Hopital Avicenne ( Site 1106)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types